FIG. 2.

(A) Distribution of targetable mutations and their frequency in metastatic TETs (thymoma plus TC; targetable mutations rate). It showed that 60% of patients harbor actable mutations at the time of metastasis. (B) The rate and type of targeted therapies used in the cohort of metastatic TETs. More than 60% of patients received at least one targeted therapy. STAT3 inhibitor was used in the context of a clinical trial. Despite the considerable risk of autoimmune flare, all patients with high TMB received immunotherapy in different trials. (C) Assessment of paired patients (same patients, n = 22) tissue and blood genomic tests. The liquid and tissue biopsies are from patients with metastatic TET. To remove the nonpathologic mutations, we included alterations with a mean allelic frequency of 20% or higher. Notably, there was a 61% overlap between liquid and blood genomic targetable alterations. Total numbers of detected targetable mutations were quite the same in liquid biopsy and tissue biopsy (17 mut v 19 mut). Tp53 mutations were reported slightly more frequently in liquid biopsy (liquid n = 8 v tissue n = 6). TC, thymic carcinoma; TETs, thymic epithelial tumors; TMB, tumor mutational burden.